Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

uh we'll see if our agent is uh additive to existing therapy. That's part of the study as well. Uh most drugs are looking like they have to be combined with some of the existing therapies. So we'll have to look at it in that context.
As Steve Palmer and other people pointed out this was really uh not our initial focus.

Correct me if I am wrong... but to me this reads as ... "we don't have something that will work on it's own like we hoped it would, so we will have to see if it works in combination with something else"

So there's still our IPF trial

And this part seems to suggest that COVID didn't work as they would expect so better hold our breath for IPF instead...

thoughts?